

The off-the-shelf, single branch device physicians trust for Zone 2 branched TEVAR procedures is **also approved for Zones 0 and 1**, expanding minimally invasive repair of all lesions involving the aortic arch.



### Zones 0 and 1:

Provides an alternative to open surgical repair and reduces the risk of complication of procedures like sternotomy, cardiopulmonary bypass and circulatory arrest.




### Zone 2:

Offers a demonstrated solution that preserves flow to the left subclavian artery (LSA) without the potential risks and complexity of surgical revascularization.




# Performance you can trust for ZONES O AND 1

TBE gives physicians an endovascular, on-label option to perfuse a single target vessel, resulting in less procedural burden for Zones 0 and 1 and delivering the results you expect.



## ZONE 2

TBE combines conformability and durability with the confidence that comes from using a proven solution from Gore.



### **EXPLORE LESS-INVASIVE** TREATMENT OPTIONS



Consider TBE for your next aortic arch repair — whether it's Zone 0, 1 or 2. From pre-case planning to device procedural consultation, we are by your side to provide support.



### **Expand your options:**

www.goremedical.com/en-emea/products/thoracic-branch-endoprosthesis

- <sup>a</sup> Core lab reported, 3 year (Total Through 36 Months(1-1275 days))
- <sup>b</sup> Embolization and thoracic stent graft placement were the reinterventions.

- 1. Butterfield K, Hsu M, Powis S, Thon M. Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch (Pivotal): Zone 0/1. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2024. [SSB 11-02 Pivotal Pre-Market Approval Study Report]. MD200865. Rev 1.
- 2. Data on file 2024; W. L. Gore & Associates, Inc; Flagstaff, AZ.
- 3. Brown J, Gorman J, Sondreaal M, Powis S. Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Descending Thoracic Aorta (Pivotal): Zone 2. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2021. [SSB 11-02 Pivotal Pre-Market Approval Study Report]. MD185099. Rev 1.

Consult Instructions for Use eifu.goremedical.com Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications. warnings, precautions and contraindications for the markets where this product is available.  $R_{cont}$ 

Products listed may not be available in all markets.

© 2025 W. L. Gore & Associates GmbH. All rights reserved. All trademarks referenced are trademarks of either a member of the Gore group of affiliated companies or their respective owners. "Together, improving life" mark and design are trademarks of a Gore company. 25AR2198-EN01 OCTOBER 2025

